Financiële Diensten Amsterdam

Financiele Diensten Amsterdam (FDA) has been providing investment advice based on a combination of independent equity research and macroeconomic analysis to investors since 1986.

  • Unbiased: FDA is completely independent and free of potential conflicts of interest. Our customers pay directly for our advice and research. We do not have a brokerage arm or derive any revenue from the transactions of our clients.
  • Focussed and Reliable: FDA strives to produce research of the highest quality, focusing on a carefully selected universe of international blue chip companies.
  • Transparent methodology: investment choices are reflected in a straightforward risk/return matrix that at any given moment reflects our preferences across the research universe.
  • Sustainable: corporate sustainability assessment is an integral part of our investment philosophy. In the long run, value can only be created if the interests of all stakeholders are dealt with in a responsible manner.
  • Affordable: the remuneration is based on returns, the value created by FDA for the client.
More about sustainability »

Products

Our customers (pension funds, banks, family offices, charity funds and other investors) benefit from FDA's expertise in several ways, depending on the size and characteristics of their portfolios:

  • access to our online research which contains the daily output of our team
  • portfolio advice, including private consultation, access to FDA Consultancy, statistical data and reporting
  • tailor-made services on demand

Sample reports

Monthly publications

Portfolios

The added value of our research is best reflected in the disciplined investment process and the outperformance of our model portfolios, such as the FDA Blue Chips Equity Portfolio.